Navigation Links
Insmed to Host Third Quarter 2010 Conference Call
Date:10/26/2010

RICHMOND, Va., Oct. 26 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday, November 3rd, at 8:30 AM ET, to discuss its financial results for the third quarter 2010.  Insmed intends to issue its quarterly financial results press release before the market opens on November 3rd.

To participate in the live conference call, please dial 866-356-4281 (U.S. callers) or 617-597-5395 (international), and provide passcode 61751565.  A live webcast of the call will also be available at http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=3461146.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on November 3rd, at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 28300679.

About InsmedInsmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs.  For more information, please visit http://www.insmed.com.

Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to business strategies, plans and objectives of management and our strategic review process, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, we may be unsuccessful in identifying or reaching agreement with acquisition or merger candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.Investor Relations Contact:Brian Ritchie – FD212-850-5683brian.ritchie@fd.comMedia Contact:Irma Gomez-Dib – FD212-850-5761Irma.gomez-dib@fd.com
'/>"/>

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
2. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
3. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
4. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
5. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
8. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
9. West to Host 2010 Third Quarter Conference Call
10. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
11. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... According to a new market research report ... Compliance, SCM), Component (Software, Service), Delivery (On premise, Cloud), End user ... MarketsandMarkets, the market is expected to reach USD 24.73 Billion by ... 13.3% during the forecast period. Continue ... ...
(Date:1/21/2017)... Jan. 20, 2017  Today, during a ... "PI3K Pathways in Immunology, Growth Disorders and ... INFI ) presented preclinical data ... that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data ... overcome resistance to checkpoint inhibition by remodeling ...
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... 2017 , ... Steviva Ingredients, makers of all-natural sweeteners and ... Organic Program (NOP) for its Portland SQF Level 2 manufacturing facility. , ... systems to complement our current rigorous food-safety management systems,” said Yishu Hou, quality ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her way ... at the Mill” is the creation of published author, Lois Kulp, who was born in ... County on Crow Hill. The inn, the mill and "Post Yokel" are within ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Bump eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where ... an international reputation for the quality of its beauty and wellness products. At this ...
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
Breaking Medicine News(10 mins):